IMM vs. ORPH, REDX, ETX, TRX, FUM, SBTX, COS, C4XD, DDDD, and POLB
Should you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), Tissue Regenix Group (TRX), Futura Medical (FUM), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), and Poolbeg Pharma (POLB). These companies are all part of the "biotechnology" industry.
ImmuPharma vs.
ImmuPharma (LON:IMM) and Open Orphan (LON:ORPH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, community ranking, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.
ImmuPharma received 266 more outperform votes than Open Orphan when rated by MarketBeat users. Likewise, 76.44% of users gave ImmuPharma an outperform vote while only 0.00% of users gave Open Orphan an outperform vote.
In the previous week, ImmuPharma and ImmuPharma both had 1 articles in the media. Open Orphan's average media sentiment score of 1.32 beat ImmuPharma's score of 0.00 indicating that Open Orphan is being referred to more favorably in the news media.
Open Orphan has higher revenue and earnings than ImmuPharma.
17.4% of ImmuPharma shares are owned by institutional investors. 48.3% of ImmuPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
ImmuPharma has a net margin of 3,519.56% compared to Open Orphan's net margin of 0.00%. Open Orphan's return on equity of 0.00% beat ImmuPharma's return on equity.
Summary
ImmuPharma beats Open Orphan on 6 of the 10 factors compared between the two stocks.
Get ImmuPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuPharma Competitors List
Related Companies and Tools
This page (LON:IMM) was last updated on 2/22/2025 by MarketBeat.com Staff
